Oncogene-induced senescence (OIS) is a tumor-suppressive mechanism — it arrests pre-malignant cells. Removing OIS-senescent cells might theoretically promote cancer. However, age-related senescent cells are distinct from OIS cells and predominantly tumor-promoting via SASP. Senolytic trials in animals consistently reduce (not increase) tumor incidence and growth.

Should cancer patients take senolytics?

Not without oncologist consultation. Established cancers have complex senescence dynamics (tumor cells may use senescence to evade treatment; tumor-promoting stroma contains senescent cells). The risk-benefit calculation is context-specific.

Does senolytic treatment increase skin cancer risk (by clearing UV-protective senescent cells)?

UV-induced senescent keratinocytes are thought to suppress neighboring UV-damaged cells. Periodic senolytic clearance is unlikely to meaningfully alter this localized protection. Sunscreen and regular dermatological screening remain essential regardless.